Issues: Vax Specific


Hepatitis B




Lyme Disease




● Smallpox



Yellow Fever


Issues: Misc




New Vax Status



Vaccine Info

2016 Schedule


IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table






About IVS

Faculty Biographies




Email IVS


Disclaimers & Privacy



ACIP Rec  VIS - ACWY VIS - MenB  WHO module  
The ACIP recommends Meningococcal Conjugate Vaccine in persons 2 years and older who are infected with HIV.  MMWR 2016;65(43):1189.

In 2012, a large retrospective cohort study of 12.6 million children and young adults from 12-21 years of age revealed no evidence of an increased risk of GBS following meningococcal vaccine. PubMed abstract | article (12-2012)

A Meingococcal vaccine that protects against Neisseria meningitidis serotype B has been approved by the US FDA.
TRUMENBA is approved for use in people 10-25 years old to protect against the disease that caused outbreaks on a few college campuses recently.     Approval of a second vaccine is anticipated in the near future; ACIP is developing guidelines for the use of these vaccines.  FDA Announcement | Trumenba package insert (10-29-14)

Recommendation of the ACIP for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease
MMWR 2011;60(40):1391. (10-14-11)

Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - ACIP, 2011   MMWR;60(30):1018.   (8-5-11)

Updated Recommendations for Use of Meningococcal Conjugate Vaccines -- ACIP, 2010  MMWR;60(03):72. (1-28-11)

Menveo, Novartis's quadrivalent meningococcal conjugate vaccine, approved by US FDA for active immunization of individuals 11 through 55 years of age to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C,Y and W-135. (2-19-10) package insert [PI updated 3/11]

Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM... A study published by Gasparini R et al in Clinical Vaccine Immunology indicates that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic, and can be co-administered with Tdap in adolescents and young adults. (2-24-10) PubMed abstract

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Halperin et al report their findings of a phase II clinical trial in a population of infants and toddlers in the European Journal of Clinical Microbiology and Infectious Disease. (03-2010) PubMed abstract.

Update on Guillain Barre Syndrome following meningococcal conjugate vaccine (Menactra): No change in recommendations for use of the vaccine.  The FDA and CDC have updated their information on Guillain Barre Syndrom (GBS) after meningococcal conjugate vaccine [link to MMWR]. GBS is a neurological disorder associated with a progressive paralysis over several days to weeks. Most people with GBS recover over a period of many weeks of months. The evidence generated by CDC and FDA suggests that there could be an increased risk of GBS of about one in one million following Menactrra in adolescents, but additional studies are needed to clearly answer this question.
Since the known risk of severe complications from meningococcal infections is high in this age group, the CDC has not altered the recommendations for routine use for adolescents, college freshmen living in dorms and others at high risk for the disease.
CDC has provided detailed information (11-01-06)

This page was last updated on December 28, 2016

2016 Institute for Vaccine Safety